Non-Small Cell Carcinoma of Lung, TNM Stage 4
Conditions
Brief summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion. This study does not intend to alter or intervene the current medical practice of the recruited patients. Data will be collected in prospective manner.
Detailed description
This is a descriptive observational study, in which data are collected in an epidemiological fashion. This study does not intend to alter or intervene the current medical practice of the recruited patients. Data will be collected in prospective manner. The eligible patients will be recruited after NGS analysis for tumor tissue and the inform-consent is obtained. The study required information will be collected (every 3 months).
Interventions
No drug intervention or tissue sampling will be included in this study.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Patients must be ≥20 years of age. 2. Provision of fully informed consent prior to any study specific procedures. 3. Histologically or cytologically confirmed, unresectable stage IIIB or stage IV NSCLC. 4. Genetic variants of tumor tissue detected by NGS.
Exclusion criteria
None.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical relevance between genomic profiling and overall survival | [ Time Frame: From registration onto that step until death, or censored at the date of last contact, assessed up to 3 years] | Kaplan-meier analysis of overall survival based on different genetic alteration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The characteristics of genomic variation and dynamic changes during different anti-tumor treatment | 24 months | Subtypes, incidence and dynamic changes of genomic variants during treatment process. |
Countries
China